Publications for Daniel ÖhmanCo-author map based on ISI articles 2007-
Journal ArticlesDaniel Öhman, Maria Dolores Cherma Yeste, Björn Norlander and Finn Bengtsson Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine Therapeutic Drug Monitoring, 2003, 25(2), 174-182. Web of Science® Times Cited: 17Daniel Öhman, Björn Norlander, Curt Peterson and Finn Bengtsson Simultaneous determination of reboxetine and O-desethylreboxetine enantiomers using enantioselective reversed-phase high-performance liquid chromatography Journal of Chromatography A, 2002, 947(2), 247-254. Web of Science® Times Cited: 22Daniel Öhman, Björn Norlander, Curt Peterson and Finn Bengtsson Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC Therapeutic Drug Monitoring, 2001, 23(1), 27-34. Web of Science® Times Cited: 26Daniel Öhman, Björn Norlander and Björn Carlsson On-line extraction using an alkyl-diol silica precolumn for racemic citalopram and its metabolites in plasma: results compared with solid-phase extraction methodology Journal of Chromatography B: Biomedical Sciences and Applications, 2001, 753(2), 365-373. Web of Science® Times Cited: 39Love Linner, Hanna Endersz, Daniel Öhman, Finn Bengtsson, Martin Schalling and Torgny Svensson Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex Journal of Pharmacology and Experimental Therapeutics, 2001, 297(2), 540-546. Web of Science® Times Cited: 82Conference ArticlesDaniel Öhman, Curt Peterson and Finn Bengtsson Development of a TDM-Method for determination of the neuroleptic compound Ziprasidone and its S-methylated main metabolite. Pharmacol Toxicol,2001, 2001. Ph.D. ThesesDaniel Öhman Bioanalytical development for application in therapeutic drug monitoring: focus on drugs used in psychiatry 2003.